Production (Stage)
Bellicum Pharmaceuticals, Inc.
BLCM
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -37.75% | -269.64% | -324.62% | -157.32% | -348.13% |
| Total Depreciation and Amortization | -62.50% | -81.40% | -85.71% | -92.03% | -94.90% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 100.33% | 106.63% | 87.34% | 105.77% | 83.49% |
| Change in Net Operating Assets | 83.27% | 138.81% | 148.21% | 37.70% | 0.63% |
| Cash from Operations | 8.23% | -36.26% | -21.93% | -11.59% | 18.23% |
| Capital Expenditure | 21.43% | 47.62% | -35.71% | -200.00% | -108.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 128.57% | 47.62% | -35.71% | -102.35% | -101.61% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | 100.00% |
| Issuance of Common Stock | -- | -- | -- | -- | 43.54% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | 868.52% |
| Foreign Exchange rate Adjustments | 80.00% | -175.00% | -550.00% | -1,700.00% | -200.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -385.98% | -311.46% | -321.34% | -342.19% | 123.59% |